Biotech Investors & VC Firms in India

108 firms in this list, with a median first check of $500K. 27 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
MB MBX Capital GBZMDRHP5 people · Follows rounds	88🔒	Claymont	US	Pre-Seed–Series A	$250K – $2.5M	+ Add to CRM
SA SABIC Ventures IFHHSBAS10 people	88🔒	Sittard	NL	Seed–Late Stage	$500K – $20M	+ Add to CRM
VE Version One Ventures BALG3 people · Leads rounds	88🔒	Vancouver	CA	Pre-Seed–Seed	$250K – $500K	+ Add to CRM
SY Sycamore Ventures PGKYTTDL14 people	88🔒	Princeton	US	Growth–Late Stage	$5M – $20M	+ Add to CRM
DE Decacorn Capital AFDMABA13 people	88🔒	Singapore	SG	Seed–Series B	$300K – $600K	+ Add to CRM
BE Better Bite Ventures MKSSFES6 people · Leads rounds	88🔒	—		Pre-Seed–Series A	—	+ Add to CRM
EV Ev3 Ventures Llc MRSG2 people · Leads rounds	88🔒	New York	US	Pre-Seed–Series A	$500K – $3M	+ Add to CRM
FR Frontline Strategy Funds AKVA2 people	88🔒	Singapore	SG	Seed–Growth	$5M – $15M	+ Add to CRM
EL Elysia Capital SBFMFBLA6 people	88🔒	Turin	IT	—	—	+ Add to CRM
PM PM Equity Partner DSSIWMAG10 people	88🔒	Lausanne	CH	Series A–Growth	$2M – $50M	+ Add to CRM
KO Kolon Investment, Inc.	88🔒	Seoul	KR	Seed–Late Stage	$3K – $22M	+ Add to CRM
AR Artiman Ventures ASBWRRTD10 people	88🔒	Palo Alto	US	Seed–Late Stage	$2M – $6M	+ Add to CRM
HB HBM Partners CLDDDUFD6 people	88🔒	Zug	CH	Pre-Seed–Late Stage	$5M – $50M	+ Add to CRM
DO DoubleRock NDSR2 people	88🔒	San Francisco	US	Seed–Series A	$2M – $15M	+ Add to CRM
VE Vertex Ventures HC CBLHYLJS4 people	88🔒	Singapore	SG	Seed–Growth	$500K – $10M	+ Add to CRM
AD AddVentures by SCG SPCLPJRM6 people	88🔒	Bangkok	TH	Seed–Late Stage	$1.5M – $66M	+ Add to CRM
ED EDB Investments CKCLCGJO11 people	88🔒	Singapore	SG	Seed–Late Stage	$12M – $400M	+ Add to CRM
JA JAFCO Asia ADRZALYS9 people	88🔒	Singapore	SG	Seed–Late Stage	$1M – $40M	+ Add to CRM
SI Simsan Ventures NGSCSCRL6 people · Leads rounds	88🔒	London	GB	Pre-Seed–Series A	—	+ Add to CRM
WE Westlake International Group	88🔒	San Mateo	US	Pre-Seed–Series A	—	+ Add to CRM
SY Syngenta Group Ventures DPJLSSMB6 people	88🔒	Durham	US	Seed–Growth	$500K – $5M	+ Add to CRM
RO Robust KA1 person · Leads rounds	88🔒	San Francisco	US	Pre-Seed–Series B	$1M – $2M	+ Add to CRM
MA Majuven LHLTLYHK4 people	88🔒	Singapore	SG	Seed–Late Stage	—	+ Add to CRM
MI Mirae Asset Venture Investment DBE(2 people	88🔒	—		Seed–Late Stage	$594K – $54M	+ Add to CRM

MBX Capital

ClaymontPre-Seed–Series A$250K – $2.5M

GBZMDRHP5 people

SABIC Ventures

SittardSeed–Late Stage$500K – $20M

IFHHSBAS10 people

Version One Ventures

VancouverPre-Seed–Seed$250K – $500K

BALG3 people

Sycamore Ventures

PrincetonGrowth–Late Stage$5M – $20M

PGKYTTDL14 people

Decacorn Capital

SingaporeSeed–Series B$300K – $600K

AFDMABA13 people

Better Bite Ventures

Pre-Seed–Series A

MKSSFES6 people

Ev3 Ventures Llc

New YorkPre-Seed–Series A$500K – $3M

MRSG2 people

Frontline Strategy Funds

SingaporeSeed–Growth$5M – $15M

AKVA2 people

Elysia Capital

Turin

SBFMFBLA6 people

PM Equity Partner

LausanneSeries A–Growth$2M – $50M

DSSIWMAG10 people

Kolon Investment, Inc.

SeoulSeed–Late Stage$3K – $22M

Artiman Ventures

Palo AltoSeed–Late Stage$2M – $6M

ASBWRRTD10 people

HBM Partners

ZugPre-Seed–Late Stage$5M – $50M

CLDDDUFD6 people

DoubleRock

San FranciscoSeed–Series A$2M – $15M

NDSR2 people

Vertex Ventures HC

SingaporeSeed–Growth$500K – $10M

CBLHYLJS4 people

AddVentures by SCG

BangkokSeed–Late Stage$1.5M – $66M

SPCLPJRM6 people

EDB Investments

SingaporeSeed–Late Stage$12M – $400M

CKCLCGJO11 people

JAFCO Asia

SingaporeSeed–Late Stage$1M – $40M

ADRZALYS9 people

Simsan Ventures

LondonPre-Seed–Series A

NGSCSCRL6 people

Westlake International Group

San MateoPre-Seed–Series A

Syngenta Group Ventures

DurhamSeed–Growth$500K – $5M

DPJLSSMB6 people

Robust

San FranciscoPre-Seed–Series B$1M – $2M

KA1 person

Majuven

SingaporeSeed–Late Stage

LHLTLYHK4 people

Mirae Asset Venture Investment

Seed–Late Stage$594K – $54M

DBE(2 people

Data sourced from public filings and firms' own websites — see our methodology.